Rhopressa (netarsudil ophthalmic solution) Drug Insight

“RHOPRESSA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about RHOPRESSA for Glaucoma in the 7MM. A detailed picture of the RHOPRESSA for Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the RHOPRESSA for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RHOPRESSA market forecast, analysis for Glaucoma in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

Drug Summary

RHOPRESSA (Netarsudil ophthalmic solution 0.02%) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Netarsudil is a Rho kinase inhibitor. Its chemical name is (S)-4-(3-amino -1-(isoquinolin-6-yl-amino)-1¬ oxopropan-2-yl) benzyl 2, 4-dimethylbenzoate dimesylate. It is known by the name RHOPRESSA in the United States and Rhokiinsa in the European Union.

It is supplied as a sterile, isotonic, buffered aqueous solution of netarsudil dimesylate with a pH of approximately 5 and an osmolality of approximately 295 mOsmol/kg. It is intended for topical application to the eye. Each mL of RHOPRESSA contains 0.2 mg of netarsudil (equivalent to 0.28 mg of netarsudil dimesylate). Benzalkonium chloride, 0.015%, is added as a preservative. The inactive ingredients are boric acid, mannitol, and sodium hydroxide, which are used to adjust pH and water for injection. The drug had completed Phase III clinical trials in Japan.

Dosage

The recommended dosage of RHOPRESSA is one drop in the affected eye once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. Twice-daily dosing is not well tolerated and therefore not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.

Mechanism of Action

Netarsudil is a Rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork route. The exact mechanism is unknown.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the RHOPRESSA description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
•  Elaborated details on RHOPRESSA regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the RHOPRESSA research and development activity in Glaucoma in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around RHOPRESSA.
•  The report contains forecasted sales of RHOPRESSA for Glaucoma till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
•  The report also features the SWOT analysis with analyst views for RHOPRESSA in Glaucoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RHOPRESSA Analytical Perspective by DelveInsight

• In-depth RHOPRESSA Market Assessment

This report provides a detailed market assessment of RHOPRESSA in Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• RHOPRESSA Clinical Assessment

The report provides the clinical trials information of RHOPRESSA in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

•  In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RHOPRESSA dominance.
•  Other emerging products for Glaucoma are expected to give tough market competition to RHOPRESSA and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RHOPRESSA in Glaucoma.
•  Our in-depth analysis of the forecasted sales data of RHOPRESSA from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RHOPRESSA in Glaucoma.

Key Questions

•  What is the product type, route of administration and mechanism of action of RHOPRESSA?
•  What is the clinical trial status of the study related to RHOPRESSA in Glaucoma and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RHOPRESSA development?
•  What are the key designations that have been granted to RHOPRESSA for Glaucoma?
•  What is the forecasted market scenario of RHOPRESSA for Glaucoma?
•  What are the forecasted sales of RHOPRESSA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Glaucoma and how are they giving competition to RHOPRESSA for Glaucoma?
•  Which are the late-stage emerging therapies under development for the treatment of Glaucoma?